IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.80+0.02 (+0.05%)
Close on Nov 13, 2026Market cap $40.48MP/E –Yield –
IRulya Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
IRulya Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $30.76M, up 7.5% year over year. For fiscal 2025 it was $35.38M, up 90.3% from the year before. The highest annual figure on record is $61.31M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.38M | +90.3% |
| FY2024 | Dec 31, 2024 | $18.59M | +96.8% |
| FY2023 | Dec 31, 2023 | $9.45M | -62.5% |
| FY2022 | Dec 31, 2022 | $25.18M | -58.6% |
| FY2021 | Dec 31, 2021 | $60.80M | -0.8% |
| FY2020 | Dec 31, 2020 | $61.31M | +102.9% |
| FY2019 | Dec 31, 2019 | $30.21M | +199.6% |
| FY2018 | Dec 31, 2018 | $10.09M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.85M | -27.6% |
| Q2 FY2026 | Jun 30, 2026 | $5.46M | -16.7% |
| Q1 FY2026 | Mar 31, 2026 | $6.85M | -16.0% |
| Q4 FY2025 | Dec 31, 2025 | $12.60M | +116.3% |
| Q3 FY2025 | Sep 30, 2025 | $8.08M | +64.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.55M | +58.0% |
| Q1 FY2025 | Mar 31, 2025 | $8.15M | +120.0% |
| Q4 FY2024 | Dec 31, 2024 | $5.83M | +69.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.92M | +243.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.15M | +206.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.70M | +14.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.43M | +24.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.43M | -41.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.35M | -81.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.23M | -74.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.77M | -81.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.45M | -82.5% |
| Q2 FY2022 | Jun 30, 2022 | $7.20M | -51.1% |
| Q1 FY2022 | Mar 31, 2022 | $12.76M | -24.2% |
| Q4 FY2021 | Dec 31, 2021 | $15.21M | -4.1% |
| Q3 FY2021 | Sep 30, 2021 | $14.04M | -17.3% |
| Q2 FY2021 | Jun 30, 2021 | $14.72M | +4.5% |
| Q1 FY2021 | Mar 31, 2021 | $16.82M | +17.0% |
| Q4 FY2020 | Dec 31, 2020 | $15.86M | +58.1% |
| Q3 FY2020 | Sep 30, 2020 | $16.98M | +105.8% |
| Q2 FY2020 | Jun 30, 2020 | $14.09M | +98.1% |
| Q1 FY2020 | Mar 31, 2020 | $14.38M | +198.0% |
| Q4 FY2019 | Dec 31, 2019 | $10.03M | +223.9% |
| Q3 FY2019 | Sep 30, 2019 | $8.25M | +260.4% |
| Q2 FY2019 | Jun 30, 2019 | $7.11M | +211.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.83M | +100.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.10M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.29M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.29M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.41M | – |
See a number that looks wrong?